COMPASS PATHWAYS PLC · held by 1 fund · data as of 2026-06-03
Sector
Healthcare
Industry
Medical Care Facilities
Market cap
$1.80B
Price
$12.97
12-mo
+170.10%
Held by
1 fund
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.